直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Patent Owners Beware: Federal Court Arguments for Broad Claim Construction May Be Used Against You in Post Grant Proceedings

October 25, 2013

Authored and Edited by Shaton C. Menzie

Patent applicants know to think carefully about the statements they make to the USPTO while working toward patent issuance. The reason? Statements made to the USPTO during patent prosecution have historically been fair game as evidence of claim limitations in issued patents. Now, thanks to the AIA, patent owners must be equally as careful when making statements about the claims of their issued patents when in Federal court. The reason? In a post grant proceeding, a party challenging the patent can use the patent owner’s statement against them as evidence that a claim is unpatentable.

Under 35 U.S.C. § 301(a)(2), any person at any time may cite to the USPTO “statements of the patent owner filed in a proceeding before a Federal court or the Office in which the patent owner took a position on the scope of any claim of a particular patent.” The legislative history explains that Congress adopted this provision to “counteract the ability of patent owners to offer differing interpretations of prior art in different proceedings,”and, moreover, to “allow the Office to identify inconsistent statements made about claim scope—for example, cases where a patent owner successfully advocated a claim scope in district court that is broader than the broadest reasonable construction that he now urges in an inter partes review.

Section 301(a)(2) is Congress’ attempt to keep patent owners honest. This provision prevents patentees from first arguing that a claim’s “correct” construction is extremely broad before the district court (in an effort to ensure that their claims cover the accused infringing technology), but subsequently arguing that the claim’s “broadest reasonable construction” is narrower in post grant proceedings before the USPTO. See Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (clarifying that district courts will give disputed terms their “correct” construction, while the USPTO will give claim terms their “broadest reasonable construction.”).

Accordingly, patent owners litigating in Federal court should take care when characterizing the scope of patent claims, lest those characterizations undermine their ability to defend that patent in post grant proceedings. Though Section 301(a)(2) does not apply to statements made in the U.S. International Trade Commission (ITC), since the ITC is not a Federal court, prudence dictates that patentees exercise caution in making statements about claim scope in that forum, as well.

Tags

claim construction, patent owner, United States Patent and Trademark Office (USPTO)

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP